Evaluation of postoperative administration of tranexamic acid on reducing blood loss after hip prothesis surgery.

Phase 1

• Conditions: Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]; surgery for hip prosthesis or for hip prosthesis replacement; MedDRA version: 18.0Level: LLTClassification code 10044088Term: Total hip replacementSystem Organ Class: 100000004865

• Registration Number: EUCTR2013-000791-15-FR
• Lead Sponsor: CHU de Saint-Etienne

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-09-24
• Study Completion: 2016-01-27
• Last Update Posted: 6 July 2020

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 168

Inclusion Criteria

- 18 or more
- needing a hip replacement surgery
- signed informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 168
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 168

Exclusion Criteria

- patients with contraindication to tranexamic acid
- patients with contraindication to preventing veinous thromboembolism by Apixaban
- patients with a preoperative effective dose anticoagulant
- pregnant woman

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified